Companies › SAb Biotherapeutics
1 active drug program in 1 registered trial: 1 Phase 2; Metabolic and endocrine; next expected readout Nov 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| SAB-142 Human anti-thymocyte immunoglobulin | THRA | Phase 2 | Type 1 Diabetes | Nov 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07187531 | SAB-142 | Phase 2 | Type 1 Diabetes | Metabolic and endocrine | Nov 2027 |
Cash and short-term investments of $104m on 2026-09-30; operating cash outflow about $50m a year; runway about 25 months at that burn, to Oct 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Rare Thyroid Therapeutics International Yarrow Bioscience Vogenx Zhuhai Rui-Inno Pharmaceutical Technology Tonghua Dongbao Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.